Saturday, March 15, 2025 | 09:07 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Lupin gets USFDA nod to market its skin conditions cream

Image

Press Trust of India New Delhi
Drug firm Lupin today said it has received final nod from the US health regulator to market its Clobetasol Propionate cream used for the treatment of various skin conditions.

The company has received final approval to market its generic Clobetasol Propionate cream USP, 0.05 per cent, from the United States Food and Drug Administration (USFDA), Lupin said in a statement.

The company's product is a generic version of Fougera Pharmaceuticals Inc's Temovate cream, it added.

The cream "is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses," it added.

Shares of Lupin Ltd today closed 2.30 per cent lower at Rs 863.35 per scrip on BSE.

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 01 2018 | 4:15 PM IST

Explore News